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Abstract 
Creatine deficiency syndromes, due to deficiencies in AGAT, GAMT (creatine synthesis 
pathway) or SLC6A8 (creatine transporter), lead to complete absence or very strong decrease 
of creatine in CNS as measured by magnetic resonance spectroscopy. Brain is the main organ 
affected in creatine-deficient patients, who show severe neurodevelopmental delay and 
present neurological symptoms in early infancy. AGAT- and GAMT-deficient patients can be 
treated by oral creatine supplementation which improves their neurological status, while this 
treatment is inefficient on SLC6A8-deficient patients. While it has long been thought that 
most, if not all, of brain creatine was of peripheral origin, these last years have brought 
evidence that creatine can cross blood-brain barrier, however only with poor efficiency, and 
that CNS must ensure parts of its creatine needs by its own endogenous synthesis. Moreover, 
we showed very recently that in many brain structures including cortex and basal ganglia, 
AGAT and GAMT, while found in every brain cell types, are not co-expressed but are rather 
expressed in a dissociated way. This suggests that to allow creatine synthesis in these 
structures, guanidinoacetate must be transported from AGAT- to GAMT-expressing cells, 
most probably through SLC6A8. This new understanding of creatine metabolism and 
transport in CNS will not only allow a better comprehension of brain consequences of 
creatine deficiency syndromes, but will also contribute to better decipher creatine roles in 
CNS, not only in energy as ATP regeneration and buffering, but also in its recently suggested 
functions as neurotransmitter or osmolyte. 
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Introduction 
 
The creatine (Cr) / phosphocreatine (PCr) / creatine kinase (CK) system plays essential roles 
to maintain the high energy levels necessary for brain development and functions, through 
regeneration and buffering of ATP levels (Wallimann et al. 1992; Wyss and Kaddurah-Daouk 
2000; Wallimann et al. 2007; Brosnan and Brosnan 2007; Andres et al. 2008). Recent works 
suggest that creatine in CNS may also act as true neurotransmitter and one of the main CNS 
osmolytes (Bothwell et al. 2002; Almeida et al. 2006). In mammals, half of Cr is obtained 
from diet, the other half being synthesized endogenously by a two-step mechanism involving 
L-arginine:glycine amidinotransferase (AGAT) and guanidinoacetate methyltransferase 
(GAMT). Cr is distributed by blood to tissues and taken up by cells through a specific Cr 
transporter, SLC6A8, also abbreviated CT1, CRTR, CTR or CreaT (Wyss and Kaddurah-
Daouk 2000).  
 
Cr deficiency syndromes are caused by mutations in AGAT, GAMT and SLC6A8 genes 
(Stöckler et al. 1994; Salomons et al. 2001; Item et al. 2001). Their common phenotype is an 
almost complete lack of Cr in CNS, as measured by magnetic resonance spectroscopy (MRS), 
CNS appearing as the main organ affected in these primary Cr deficiencies. Patients develop 
severe neurodevelopmental delay and present neurological symptoms in early infancy, like 
mental retardation, delays in speech acquisition or epilepsy (Stöckler et al. 2007). Oral Cr 
supplementation strongly improves the neurological status of AGAT- and GAMT-deficient 
patients (Stöckler et al. 1996; Schulze et al. 1998; Battini et al. 2002; Schulze and Battini 
2007), while this treatment is inefficient on SLC6A8-deficient patients (Bizzi et al. 2002; 
Póo-Argüelles et al. 2006; Arias et al. 2007). Secondary Cr deficiencies are also observed in 
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other pathological states of the brain, like stroke, hyperammonemic states or gyrate atrophy of 
the choroid and retina (GA) (Valle et al. 1981; Braissant et al. 2008; Lei et al. 2009). 
 
It has long been thought that most, if not all, cerebral Cr was of peripheral origin (Wyss and 
Kaddurah-Daouk 2000). However, AGAT and GAMT are expressed in CNS and brain cells 
synthesize their own Cr (Braissant et al. 2001b; Braissant et al. 2002). In contrast, while 
SLC6A8 is expressed by microcapillary endothelial cells (MCEC) at blood-brain barrier 
(BBB), allowing CNS to import Cr from periphery, it is absent from astrocytes, at least in 
physiological conditions, and particularly from their feet lining MCEC (Figure 1; Braissant et 
al. 2001b; Ohtsuki et al. 2002; Tachikawa et al. 2004). This made us suggest that BBB has a 
limited permeability for peripheral Cr, and that CNS must supply an important part of its Cr 
needs by endogenous synthesis rather than on an exclusive supply from the blood (Braissant 
et al. 2001b; Braissant and Henry 2008). As in periphery with predominant expression of 
AGAT in kidney and GAMT in liver (Edison et al. 2007; da Silva et al. 2009), very recent 
data also suggest that the Cr synthesis pathway may be dissociated in CNS, guanidinoacetate 
(GAA) being transported through SLC6A8 from AGAT- to GAMT-expressing brain cells for 
Cr synthesis to occur (Braissant et al. 2010). 
 
This review is focused on Cr deficiency syndromes and their effects on the brain in view of 
the latest data on Cr synthesis and transport in CNS, in order to delineate a comprehensive 
frame on Cr metabolism and transport in CNS, both in normal and Cr-deficient conditions. 
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Creatine deficiency syndromes 
 
CNS is the main organ affected in patients suffering from the Cr deficiency syndromes, 
inborn errors of Cr biosynthesis and transport caused by AGAT, GAMT or SLC6A8 
deficiency which are characterized by an absence or a severe decrease of Cr in CNS as 
measured by MRS (Stöckler et al. 1994; Salomons et al. 2001; Item et al. 2001). AGAT and 
GAMT deficiencies are autosomal recessive diseases, while SLC6A8 deficiency is an X-
linked disorder. Cr deficiency syndromes appear among the most frequent inborn errors of 
metabolism (IEM), the prevalence of SLC6A8 deficiency being estimated at 2% of all X-
linked mental retardations (Rosenberg et al. 2004) and at 1% of males with mental retardation 
of unknown etiology (Clark et al. 2006). AGAT and GAMT deficiencies are rarer, but the 
prevalence of all combined Cr deficiencies was estimated between 0.3% and 2.7% of all 
mental retardation (Lion-François et al. 2006; Arias et al. 2007). 
 
Cr-deficient patients present neurological symptoms in infancy (Schulze et al. 1997; Battini et 
al. 2002; DeGrauw et al. 2002). In particular, mental retardation and delays in speech 
acquisition can be observed (AGAT, GAMT and SLC6A8 deficiencies), as well as intractable 
epilepsy (GAMT and SLC6A8 deficiencies), autism, automutilating behavior, extrapyramidal 
syndrome and hypotonia (GAMT deficiency) (Stöckler et al. 2007). The diverse phenotypic 
spectrum of neurological symptoms observed in AGAT, GAMT and SLC6A8 deficient 
patients show the importance of Cr for psychomotor development and cognitive functions and 
is probably explained by the wide pattern of AGAT, GAMT and SLC6A8 expression in the 
mammalian brain (see below). The recently proposed roles of Cr as co-transmitter on GABA 
postsynaptic receptors (Almeida et al. 2006) and of regulator of appetite and weight on 
specific hypothalamic nuclei (Galbraith et al. 2006) might also contribute to this phenotypic 
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diversity. The more complex phenotype of GAMT deficiency, including intractable epilepsy, 
extrapyramidal movement syndromes and abnormalities in basal ganglia is probably due to 
the toxicity, and particularly the epileptogenic action, of brain GAA accumulation 
characteristic of GAMT deficiency (Schulze et al. 2001), which may occur through activation 
of GABAA receptors by GAA (Neu et al. 2002). GAA may also inhibit the complex between 
Na+/K+-ATPase and CK (Zugno et al. 2006). Severe epilepsy may also appear in SLC6A8-
deficient patients (Mancardi et al. 2007). This may be due to the observed CNS GAA 
accumulation in some SLC6A8-deficient patients (Sijens et al. 2005), that could be caused by 
impairment of GAA transport through deficient SLC6A8, from AGAT- to GAMT-expressing 
brain cells (see below) (Braissant et al. 2010). 
  
Treatments and outcome of Cr deficiency syndromes  
 
AGAT- and GAMT-deficient patients can be treated by oral supplementation of Cr. While 
this strongly improves their neurological status and CNS development, very high doses of Cr 
must be used, and replenishment of cerebral Cr takes months and only results, in most cases, 
in partial restoration of cerebral Cr pools (Stöckler et al. 1996; Ganesan et al. 1997; Item et al. 
2001; Battini et al. 2002). For GAMT-deficient patients, combined arginine restriction and 
ornithine substitution coupled to Cr treatment decrease GAA and also improve clinical 
outcome (Schulze et al. 1998; Schulze et al. 2001). Despite improvement of clinical outcome 
by Cr supplementation, most AGAT- and GAMT-deficient patients remain with CNS 
developmental problems. However, the pre-symptomatic treatment of AGAT- and GAMT-
deficient patients appears to prevent, so far, most of the Cr deficiency effects on their brain 
(Battini et al. 2006; Schulze et al. 2006; Schulze and Battini 2007). Oral supplementation of 
Cr is inefficient in replenishing brain Cr in SLC6A8-deficient patients, who remain with 
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mental retardation, severe speech impairment and progressive brain atrophy (Cecil et al. 2001; 
Bizzi et al. 2002; DeGrauw et al. 2002; Póo-Argüelles et al. 2006). Attempts to treat 
SLC6A8-deficient patients with arginine as precursor of Cr also failed to improve their 
neurological status (Fons et al. 2008). Similarly, the use of a lipophilic Cr-derived compound, 
creatine ethyl ester, failed to replenish brain Cr concentration in SLC6A8-deficient patients, 
as well as to improve their neurological status (Fons et al. 2010). 
 
Secondary creatine deficiencies in CNS 
 
Several other CNS pathologies have been identified that cause a secondary Cr deficiency in 
brain cells. Excess of ammonium (NH4
+) is toxic for CNS. In pediatric patients, 
hyperammonemia can be caused by various acquired or inherited disorders, the most frequent 
being urea cycle diseases, which can cause irreversible damages to the developing brain 
(Leonard and Morris 2002) by altering several amino acid pathways and neurotransmitter 
systems, nitric oxide synthesis, axonal and dendritic growth and signal transduction pathways 
(Cagnon and Braissant 2007; Cagnon and Braissant 2008; Cagnon and Braissant 2009) 
eventually leading to energy deficit, oxidative stress and cell death (Braissant 2010b). In 
particular, NH4
+ exposure generates a secondary Cr deficiency in brain cells (Ratnakumari et 
al. 1996; Choi and Yoo 2001; Braissant et al. 2002). NH4
+ appears to inhibit AGAT enzymatic 
activity and differentially alters AGAT, GAMT and SLC6A8 gene expression in a cell type-
specific manner, which may alter the energy requirements of brain cells (Braissant et al. 2008; 
Braissant 2010a). Ischemic stroke in CNS leads to a rapid diminution in brain total Cr (Cr + 
PCr) (Obrenovitch et al. 1988; Gideon et al. 1992; Mathews et al. 1995; Lei et al. 2009). This 
lower Cr level in stroke causes a decrease in high energy phosphate production, and leads to a 
failure in most energy-dependent processes necessary for cell survival. Gyrate atrophy of the 
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choroid and retina (GA) is an inborn error of metabolism leading to blindness in the first 10 
years of life and is caused by mutations in ornithine -aminotransferase (OAT) (Valle et al. 
1981). OAT deficiency generates a secondary Cr deficiency, as it generates an important 
ornithine accumulation facilitating the reversed AGAT reaction, therefore depleting GAA for 
Cr synthesis (Sipilä 1980). This is particularly true in CNS, where GA neurological symptoms 
may be related to this secondary Cr deficiency (Näntö-Salonen et al. 1999; Valayannopoulos 
et al. 2009). 
 
AGAT, GAMT and SLC6A8 in CNS 
 
Cr is synthesized in the mammalian brain (Pisano et al. 1963; Van Pilsum et al. 1972), in 
nerve cell lines as well as in primary and organotypic brain cell cultures (Daly 1985; Dringen 
et al. 1998; Braissant et al. 2002). AGAT and GAMT are expressed in CNS, where they are 
found in all the main structures of the brain, in every main cell types (neurons, astrocytes and 
oligodendrocytes, Figure 1; Braissant et al. 2001b; Tachikawa et al. 2004; Schmidt et al. 
2004; Nakashima et al. 2005). Moreover, we have shown very recently that in most region of 
the rat brain, AGAT and GAMT appear rarely co-expressed within the same cell (see below; 
Braissant et al. 2010). Organotypic rat cortical cultures, primary brain cell cultures (neuronal, 
glial or mixed) and neuroblastoma cell lines have a Cr transporter activity (Möller and 
Hamprecht 1989; Almeida et al. 2006; Braissant et al. 2008). In vivo, mouse and rat CNS can 
take up Cr from the blood against its concentration gradient (Ohtsuki et al. 2002; Perasso et 
al. 2003). SLC6A8 is expressed throughout the main regions of adult mammalian brain 
(Schloss et al. 1994; Happe and Murrin 1995; Braissant et al. 2001b; Tachikawa et al. 2008; 
Mak et al. 2009). In the first detailed analyses of Cr transporter expression in CNS, it was 
demonstrated that SLC6A8 is found in neurons and oligodendrocytes but, in contrast to 
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AGAT and GAMT, cannot be detected in astrocytes (Figure 1; Braissant et al. 2001b), except 
for very rare ones in cerebellum (Mak et al. 2009).  This holds true also for the retina, where 
SLC6A8 is expressed in retinal neurons, but not in astrocytes (Nakashima et al. 2004; Acosta 
et al. 2005). In contrast to its absence in astrocytes lining microcapillaries, SLC6A8 is present 
in MCEC making BBB (Braissant et al. 2001b; Ohtsuki et al. 2002; Tachikawa et al. 2004). 
 
It must be emphasized also that AGAT, GAMT and SLC6A8 are expressed very differently 
by brain cells, depending whether the analysis is made in vivo or in vitro, as well as in vitro 
depending on the type of cultures. 20 years ago, an important paper by Möller and Hamprecht 
showed a detailed description of the in vitro Cr uptake capacity of numerous types of primary 
brain cells, as well as immortalized cell lines, all cultured in presence of serum. They 
concluded that astrocytes have the highest activity of Cr transporter (Möller and Hamprecht 
1989). We showed that in vivo AGAT and GAMT can be found in all brain cell types, while, 
in contrast to what was demonstrated in primary cultures of astrocytes, SLC6A8 is not 
expressed by astrocytes (Braissant et al. 2001b). We further demonstrated that organotypic 
cultures like brain 3D mixed-cell aggregates cultured in absence of serum synthesize their 
own Cr and express AGAT, GAMT and SLC6A8 as the in vivo CNS, including the absence 
of SLC6A8 from astrocytes (Braissant et al. 2008). In contrast, when we analyzed brain 3D 
neuron-enriched aggregates also cultured in absence of serum, from which astrocytes and 
oligodendrocytes have been eliminated, we showed that in absence of glial cells, AGAT and 
GAMT are totally silent from neurons and from the very few remaining astrocytes, while both 
genes are well expressed in both cell types when glial cells are present (Braissant et al. 2008). 
It is known that brain cells cultured as 2D monolayers or in presence of serum develop a 
pathological reactive state that completely alters their behavior in terms of gene expression 
and protein activities. This is particularly true for astrocytes, which develop constant reactive 
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gliosis as illustrated by their increase in GFAP and vimentin expression as compared to in 
vivo conditions (Langan and Slater 1992; F.Tschudi-Monnet and P.Honegger, personal 
communication; and unpublished results). We have shown that SLC6A8, which is silent in 
astrocytes in vivo as well as in 3D brain cells aggregates cultured in absence of serum, is 
activated in these same astrocytes when they are placed in a reactive state (in that case 
exposure to ammonium; Cagnon and Braissant 2007; Braissant et al. 2008; Braissant 2010b). 
It appears thus that most models of cultured brain cells, in particular when cultured in 
presence of serum, do not behave as the in vivo CNS for Cr metabolism and transport. Thus, 
to analyze Cr in brain cells in conditions as near as possible of the in vivo CNS, complex 3D, 
organotypic and mixed-cell culture systems in absence of serum should be used (Braissant 
2010a).  
 
Creatine in CNS: Endogenous synthesis versus uptake from periphery ? 
 
The in vivo expression of AGAT and GAMT within mammalian CNS, as well as the in vitro 
endogenous synthesis of Cr by various types of cultured brain cells, including primary and 
organotypic cultures, suggest that brain synthesizes Cr (Braissant et al. 2007). However, it 
was thought for a long time that most, if not all, of the Cr needed by CNS comes from 
periphery through BBB (Wyss and Kaddurah-Daouk 2000). 
 
The discovery that SLC6A8 cannot be detected in astrocytes, particularly in their feet 
sheathing MCEC made us suggest however that in mature CNS, BBB has a limited 
permeability for Cr, despite SLC6A8 expression by MCEC and their capacity to import Cr 
(Braissant et al. 2001b; Ohtsuki et al. 2002; Tachikawa et al. 2004; Nakashima et al. 2004; 
Acosta et al. 2005). In vivo data confirmed this hypothesis: the blood to brain transport of Cr 
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through BBB is effective in rats and mice but is relatively inefficient (Ohtsuki et al. 2002; 
Perasso et al. 2003), and long term treatment of AGAT- and GAMT-deficient patients with 
high doses of Cr allows only a slow and in most cases partial replenishment of their brain Cr 
pools (Stöckler et al. 2007; Schulze and Battini 2007). Similarly, GAMT-/- KO mice treated 
with high doses of Cr replenish their brain Cr, but only slowly (Kan et al. 2007). The effective 
but limited entry of Cr from blood to CNS through MCEC but without going through 
astrocytes may occur through the limited surface of CNS microcapillary endothelium that is 
free of astrocytic feet (Figure 1; Virgintino et al. 1997; Ohtsuki 2004).  
 
One strong argument in favor of the “brain endogenous Cr synthesis” hypothesis comes from 
Cr measures in the CSF of Cr-deficient patients (see Braissant and Henry 2008, and 
references therein). SLC6A8 deficient patients present normal Cr levels in CSF, but are 
strictly unable to import Cr from periphery (Cecil et al. 2001; DeGrauw et al. 2002; Bizzi et 
al. 2002; Póo-Argüelles et al. 2006). In contrast, GAMT-deficient patients show strongly 
decreased levels of Cr in CSF but are able to import Cr from the blood (Stöckler et al. 1994; 
Schulze et al. 1997). This also suggests that Cr synthesis in the brain might still remain 
operational, although very partially, under SLC6A8 deficiency, while it is completely blocked 
in AGAT and GAMT deficiencies. Endogenous synthesis, or a very efficient uptake from 
periphery, are the two ways available for the brain to secure Cr homeostasis for its energy and 
functions. As uptake from periphery does not appear efficient, CNS might privilege Cr 
endogenous synthesis. The brain capacity for Cr synthesis would thus depend on the efficient 
supply of arginine, the limiting substrate for Cr synthesis, from blood to CNS, and then also 
on local trafficking of arginine between brain cells. We and others have shown that cationic 
amino acid transporters (CATs) might fulfill these roles in the brain, as CAT1 is expressed in 
MCEC as well as ubiquitously in neuronal and glial cells, as CAT2(B) is present in neurons 
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and oligodendrocytes, and as CAT3 is restricted to neurons (Braissant et al. 1999; Hosokawa 
et al. 1999; Braissant et al. 2001a). 
 
The hypothesis of endogenous Cr synthesis in the brain might seem contradictory with the in 
vivo characteristics of SLC6A8 deficiency, which, despite AGAT and GAMT expression in 
CNS, presents an absence (or a very low level) of brain Cr by MRS (Salomons et al. 2001). 
This apparent contradiction is probably explained by our very recent data on AGAT, GAMT 
and SLC6A8 expression patterns in the brain. AGAT and GAMT are found in every CNS cell 
type (Braissant et al. 2001b), but appear rarely co-expressed within the same cell (Braissant et 
al. 2010). This suggests that to allow Cr synthesis in the brain, GAA must be transported from 
AGAT- to GAMT-expressing cells (Figure 1). This GAA transfer most probably occurs 
through SLC6A8, as shown in the same study by Cr and GAA competition studies and the use 
of stable isotope-labeled GAA demonstrating its uptake by brain cells followed by its 
conversion to Cr by GAMT activity (Braissant et al. 2010). These observations may explain 
the Cr absence in CNS of SLC6A8-deficient patient, despite normal expression of AGAT and 
GAMT in their brain (Braissant and Henry 2008), as well as the lack of effect of treatment of 
SLC6A8-deficient patients with arginine as precursor of Cr (Fons et al. 2008). Recent studies 
also demonstrated the potential role of SLC6A8 (and taurine transporter) for GAA transport 
across BBB and in brain parenchymal cells (Tachikawa et al. 2008; Tachikawa et al. 2009).  
 
While we have shown that AGAT and GAMT can be found in all brain cell types (Braissant 
et al. 2001b), other studies demonstrated particularly high levels of GAMT in glial cells 
(Schmidt et al. 2004; Tachikawa et al. 2004; Braissant et al. 2008), suggesting that the final 
CNS step for Cr synthesis may predominantly by glial. However, this probably depends on 
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the brain region considered, as in cortex, only 20% of astrocytes express GAMT, in 
comparison with 48% of neurons (Braissant et al. 2010). 
 
Adult versus developmental CNS 
 
As described above, the adult (or mature) brain might privilege Cr endogenous synthesis 
versus uptake from periphery, due to low permeability of BBB for Cr and thank to the 
expression of AGAT and GAMT in CNS parenchyma. Fetal and perinatal (or immature) CNS 
probably behaves differently for its Cr needs.  
 
The Cr/PCr/CK system plays essential roles in energy homeostasis during vertebrate 
embryonic development (Wallimann et al. 1992), the fetal needs in Cr being partly supported 
by active transport of Cr from mother to fetus (Davis et al. 1978; Ireland et al. 2008). On the 
other hand, AGAT, GAMT and SLC6A8 are also well expressed during vertebrate 
embryogenesis, including in the brain (Schloss et al. 1994; Sandell et al. 2003; Schmidt et al. 
2004; Braissant et al. 2005; Wang et al. 2007; Ireland et al. 2009). We have shown that 
AGAT and GAMT are expressed in the whole developing CNS parenchyma (Braissant et al. 
2005). However, their low level (GAMT in particular) at early developmental stages suggests 
that in contrast to adult brain, embryonic CNS depends predominantly on external Cr supply, 
be it from embryonic periphery or from maternal origin. This is coherent with SLC6A8 
expression in the whole embryonic CNS already at early stages (E12.5 in rat), with 
particularly high levels in periventricular zone and choroid plexus, the predominant metabolic 
exchange zones of fetal CNS before microcapillary angiogenesis and differentiation of BBB 
(Braissant et al. 2005; Braissant et al. 2007). 
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Creatine and guanidinoacetate within normal versus creatine-deficient CNS 
 
In normal conditions, Cr within human CSF is maintained in the 17-90µM range, while GAA 
is maintained at a 1000x lower level (0.015-0.114µM). By MRS, total Cr is measured 
between 5.5mM and 6.4mM in the cortical gray matter, while GAA was estimated to 1.6mM 
(see Braissant and Henry 2008, and references therein). 
 
With the exception of SLC6A8-deficient heterozygous females where brain Cr deficiency is 
partial (Cecil et al. 2003), all three Cr deficiencies present the virtual absence of the Cr peak 
measured by MRS in cortex and basal ganglia (Stöckler et al. 2007). However, despite this 
lack of Cr detection by MRS, Cr remains present within the brain of Cr-deficient patients. In 
SLC6A8 deficiency, Cr CSF levels do not differ from age-matched controls (Cecil et al. 2001; 
Salomons et al. 2001; DeGrauw et al. 2002). In AGAT deficiency, total Cr levels in cortical 
gray matter are decreased to 12% of age-matched controls (Battini et al. 2002). In GAMT 
deficiency, CSF Cr levels are strongly decreased (<2µM) (Schulze et al. 1997; Schulze et al. 
2003; Ensenauer et al. 2004), while in cortical gray matter total Cr was measured in the 0.2-
1.5mM range (Stöckler et al. 1994; Mancini et al. 2005). 
 
GAA accumulation in body fluids is characteristic of GAMT deficiency, where its toxicity is 
responsible for the more complex and specific phenotype of GAMT-deficiency (see above). 
GAA CSF levels in GAMT-deficient patients are 60-1000x higher than in age-matched 
controls, while GAA was estimated to 3.6mM within cortical gray matter. No precise data are 
available on GAA levels within AGAT- and SLC6A8-deficient CNS, but it was shown that 
GAA can also accumulate in the brain of SLC6A8-deficient patients (Sijens et al. 2005). As 
described above, GAA may appear as a key intermediate player for endogenous Cr synthesis 
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in CNS, as it must most probably be transported from AGAT- to GAMT-expressing cells for 
Cr synthesis to occur (Braissant et al. 2010), just as it does in periphery between AGAT in 
kidney and GAMT in liver (Edison et al. 2007; da Silva et al. 2009). It was recently 
demonstrated that both BBB endothelial cells (Tachikawa et al. 2009) and CNS parenchymal 
cells (Tachikawa et al. 2008; Braissant et al. 2010) are able to take up GAA by SLC6A8. The 
Km value of SLC6A8 for GAA appears 10 times lower than that for Cr (Tachikawa et al. 
2008). Thus, entry of GAA into CNS in normal conditions must be inhibited by blood Cr 
levels (1-3.5µM for GAA versus 6-50µM for Cr). This entry might however be facilitated 
under GAMT deficiency, blood GAA levels becoming higher than Cr levels (12-39µM for 
GAA versus 1-5µM for Cr) (Almeida et al. 2004), therefore contributing to GAA 
accumulation into the GAMT-deficient brain. 
 
Models for creatine synthesis and trafficking in CNS 
 
Taken together, (i) the absence of Cr within the brain of Cr-deficient patients, (ii) the CNS 
expression patterns of AGAT, GAMT and SLC6A8, (iii) the low permeability of BBB for Cr, 
and (iv) the measures of Cr and GAA within CNS both in normal and Cr-deficient conditions, 
lead us to propose the following model to understand Cr synthesis and trafficking within the 
brain (Figure 1) (Braissant and Henry 2008): 
 
In normal conditions, SLC6A8 is expressed by MCEC, but not by the surrounding astrocytic 
feet, implying that limited amounts of Cr can enter the brain through BBB. In most brain 
regions (including cortex and basal ganglia, where most MRS measures are performed), brain 
cells express AGAT and GAMT in a cell-dissociated way, and GAA must be transported from 
AGAT- to GAMT-expressing cells by SLC6A8 for Cr synthesis to occur. In AGAT and 
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GAMT deficiency, no Cr can be synthesized within CNS, but SLC6A8 expression in MCEC 
allows the limited entry of Cr within the brain, and thus their treatment by oral Cr and the 
partial replenishment of the brain Cr pools. Moreover, the brain of GAMT-deficient patients 
accumulates GAA. Cr transporter-deficient patients lack functional SLC6A8 on MCEC, and 
thus cannot be treated by oral Cr. Moreover, their endogenous CNS Cr synthesis pathway is 
also deficient, as in most brain regions, GAA cannot cross from AGAT- to GAMT-expressing 
cells due to their lack in functional SLC6A8. 
 
Conclusion  
 
Brain is the main organ affected in Cr deficiency syndromes due to deficiencies in AGAT, 
GAMT or SLC6A8, which lead to a complete absence or a very strong decrease of Cr in CNS. 
AGAT- and GAMT-deficient patients can be treated by oral creatine supplementation which 
improves their neurological status, while this treatment is inefficient on SLC6A8-deficient 
patients. The recent years have brought new knowledge on Cr metabolism and transport in the 
brain, allowing a better understanding on the pathophysiology of Cr deficiency syndromes in 
brain cells. In particular, there is evidence that BBB presents a low permeability for Cr, and 
that CNS must ensure parts of its needs in Cr by endogenous synthesis. Moreover, in many 
regions of the brain, Cr endogenous synthesis appears to be dissociated, GAA needing to be 
transported by SLC6A8 from AGAT- to GAMT-expressing cells for Cr synthesis to occur. 
This probably explains why, despite AGAT and GAMT expression in their brain, SLC6A8-
deficient patients remain with a Cr-depleted CNS. 
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Figure legends 
 
Figure 1 : Creatine synthesis and transport in central nervous system: model illustrating 
endogenous synthesis versus uptake from periphery, including the various combinations 
of AGAT, GAMT and SLC6A8 expression within brain cells (Braissant et al. 2010). 1) 
Cr endogenous synthesis within cells co-expressing AGAT and GAMT. 2) Cr endogenous 
synthesis through AGAT-expressing cells synthesizing GAA, and GAA uptake by SLC6A8 in 
GAMT-expressing cells; this conformation appears the prevalent one in most brain regions. 3) 
Cells expressing only SLC6A8 (“users” of Cr). 4) Cells silent for AGAT, GAMT and 
SLC6A8. While microcapillaries express SLC6A8, astrocytic feet lining them do not. This 
implies that only low amounts of peripheral Cr can enter the brain through the limited 
endothelial surface that is free of astrocytic feet, and that CNS must also ensure its own 
endogenous synthesis of Cr. So far, the way Cr (and GAA) can leave cells is poorly known. 
Cr: creatine; AGAT: L-arginine:glycine amidinotransferase; GAMT: guanidinoacetate 
methyltransferase; GAA: guanidinoacetate; SLC6A8: Cr transporter. 
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